Nanoparticle-RNA for Diabetic Foot Ulcers

About Ceria Therapeutics

Ceria Therapeutics is a private, pre-clinical stage biotech founded in 2021, headquartered in Cambridge, MA, with operations in Tucson, AZ, and San Juan, PR. The company's core innovation is a platform for delivering RNAi therapeutics via cerium oxide (a lanthanide) nanoparticles, initially targeting inflammatory conditions in wound care, critical care, and gastrointestinal care. Ceria employs a hybrid business model, advancing its own drug candidates while generating non-dilutive funding and validation through its manufacturing services and significant government grants from the NIH and Department of Defense. Its near-term strategy focuses on advancing lead programs for diabetic foot ulcers and acute lung injury toward clinical development.

Therapeutic Areas

Other Non-healing Diabetic Foot Ulcers Drugs